A brighter future for Monoclonal Antibodies
BIOPURE Project
Monoclonal antibodies (mAbs) form an essential part of biological medicines by providing essential support to our body’s immune system. However, these antibodies are produced in laboratories through processes that can be costly and time-consuming.
The BIOPURE Project seeks to make the purification of mAbs as simple and efficient as possible through an innovative technology that streamlines logistical chains and promotes sustainability by avoiding extensive use of chemicals.
A Healthy Ambition
BIOPURE aims to lower manufacturing and equipment costs associated with mAbs purification, leading to new opportunities in the field of biomedicine that were previously too costly or technologically challenging to utilise.
Our innovation is focused on giving patients greater access to more affordable and effective next-generation biomedicines. BIOPURE has been funded under the highly competitive EIC Transition call.
Our Partners
The BIOPURE consortium comprises a multidisciplinary group of internationally recognised biopharmaceutical experts and
companies across 3 EU member states.
NEWS
